Compare Moderna, Inc. (MRNA) vs Ralph Lauren Corp (RL) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Moderna, Inc. vs Ralph Lauren Corp — how do they compare? Moderna, Inc. trades at $61.72 (market cap $24.18B), while Ralph Lauren Corp trades at $391 (market cap $23.70B). The key difference: Moderna, Inc. and Ralph Lauren Corp are close in size by market cap, and Ralph Lauren Corp pays a 0.94% dividend while Moderna, Inc. pays none. Which is the better fit depends on your goals.
| MRNA | RL | |
|---|---|---|
Market Cap | $24.18B | $23.70B |
Sector | Health | Consumer Cyclical |
52-Week High | $81.80 | $414.25 |
52-Week Low | $22.36 | $285.35 |
Enterprise Value | $20.33B | $24.76B |
Dividend Yield | — | 0.94% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Moderna (MRNA) trades at $59.81, up 1.08% today, with a bullish technical signal from moving averages and recent FDA approval for its mRNA flu vaccine mFLUSIVA. Despite beating Q2 2026 EPS estimates, revenue has declined from pandemic peaks, with a net income margin of -142.58% in 2026. The stock faces resistance near $61-$63, while support lies at $56-$59.
Outlook remains mixed; pipeline advancements in flu, Ebola, and oncology offer growth potential, but persistent losses and high valuation ratios pose risks. Analyst consensus is cautious with a $54.33 price target below current levels, reflecting concerns over profitability amid transitioning business focus.
Ralph Lauren (RL) trades at $406.89, up 2.87% today, reflecting strong momentum after consecutive earnings beats. The stock shows bullish technical signals with support near $396 and resistance at $413. Fundamentals are robust, with Q2 2026 EPS of $4.59 beating estimates, revenue growth to $7.08B in 2025, and high profitability margins. Analyst sentiment is overwhelmingly positive, with 66% recommending Buy and a consensus price target of $456.50.
The outlook remains favorable due to brand strength and margin expansion, but risks include economic sensitivity and high valuation multiples. Near-term catalysts hinge on Q3 2026 earnings due soon. The stock's proximity to its 52-week high suggests cautious entry points may be optimal.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Moderna, Inc.
Moderna, Inc. operates as a clinical stage biotechnology company. The Company focuses on the discovery and development of messenger RNA (mRNA) therapeutics and vaccines. Moderna develops mRNA medicines for infectious, immuno-oncology, and cardiovascular diseases.
Read more on MRNA →About Ralph Lauren Corp
Founded by designer Ralph Lauren in 1967, Ralph Lauren Corp. designs, markets, and distributes lifestyle products in North America, Europe, and Asia. Its products include apparel, footwear, eyewear, jewelry, leather goods, home products, and fragrances. The company's brands include Ralph Lauren Collection, Polo Ralph Lauren, Lauren Ralph Lauren, and Double RL. Distribution channels for Ralph Lauren include wholesale (including department stores and specialty stores), retail (including company-owned retail stores and e-commerce), and licensing.
Read more on RL →
